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The development of convenient serumbioassays for cancer screening, diagnosis, prognosis, andmonitoring
of treatment is one of top priorities in cancer research community. Although numerous biomarker candi-
dates have been generated by applying high-throughput technologies such as transcriptomics, proteomics,
and metabolomics, few of them have been successfully validated in the clinic. Better strategies to mine
omics data for successful biomarker discovery are needed. Using a data set of 22,794 tumor and normal
samples across 23 tissues, we systematically analyzed current problems and challenges of serum bio-
marker discovery fromgene expression data.Weﬁrst performed tissue speciﬁcity analysis to identify genes
that are both tissue-speciﬁc andup-regulated in tumors compared to controls, but identiﬁed fewnovel can-
didates. Then, we designed a novel computationmethod, themultiple normal tissues corrected differential
analysis (MNTDA), to identify genes that are expected to be signiﬁcantly up-regulated even after their
expressions in other normal tissues are considered, and, in a simulation study, showed that the multiple
normal tissues corrected differential analysis outperformed the single tissue differential analysis combined
with tissue speciﬁcity analysis. By applying the multiple normal tissues corrected differential analysis, we
identiﬁed some genes as novel biomarker candidates. However, the number of potential candidates was
disappointingly small, exemplifying the difﬁculty of ﬁnding serum cancer biomarkers. We discussed a
few important points that should be considered during biomarker discovery from omics data.
 2011 Elsevier Inc. All rights reserved.1. Introduction potential biomarkers have not been accompaniedby con-current in-Developing simple non-invasive tests that allow early cancer
detection is one of top priorities in cancer research ﬁeld. Such tests
will impact patient care and outcome through disease screening
and early detection [18]. Recent high-throughput omics tools such
as transcriptomics and proteomics have produced many candidate
cancer biomarkers, raising our expectation that many simple non-
invasive biomarkerswill be developed soon.However, fewbiomark-
ers identiﬁed fromomics data analysis have been validated and suc-
cessfully translated into clinical tests [1].Mostly, largediscrepancies
exist betweenﬁndings fromomics analysis of tissue samples and re-
sults in serum analysis. Steady increases in the publications onll rights reserved.
rrected differential analysis;
arch Center, KRIBB, Daejeoncreases in the FDA-approved biomarkers [31].
Serum proteins in the circulatory system reﬂect complex phys-
iological and pathological conditions in the body with the abun-
dance range of known serum proteins encompassing nine orders
of magnitude [18]. Here, tumor-tissue derived proteins in the cir-
culation are likely to be at lower end of this range, particularly dur-
ing the early stages of tumor development [18]. For this reason,
analysis of tumor tissues has been pursued to identify differentially
expressed proteins. However, most potential biomarkers identiﬁed
from tissue analysis were not successfully validated in serum anal-
ysis [18]. One obvious reason is most tumor-tissue derived pro-
teins are diluted in the circulation as blood contains molecules
derived from all tissues. One potential way is to focus on tissue-
speciﬁc genes in which the pattern of biomarker expression in tis-
sue is expected to be similarly represented in the serum [25,26].
Prostate-speciﬁc antigen (PSA), one of the most successful serum
biomarkers, is indeed expressed only in normal prostate tissue,
and is frequently up-regulated in prostate tumors compared to
normal prostate tissues [18].
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abases such as gene expression omnibus (GEO) and ArrayExpress
allowing researchers search, download, and extract useful informa-
tion from them. We have systematically collected, processed, and
analyzed human tissue gene expression data sets produced using
Affymetrix platforms. Until now, we have collected more than
400 data sets encompassing diverse cancer and normal samples
from most tissue types and constructed a data-rich cancer gene
expression database comprising more than 22,000 samples [42].
Then, we developed a novel computational approach, the multiple
normal tissues corrected differential analysis (MNTDA), to identify
genes that are expected to be signiﬁcantly up-regulated even after
their expressions in other normal tissues are considered. In a sim-
ulation study, we showed that the MNTDA outperformed the sin-
gle-tissue level differential analysis (STDA) combined with tissue
speciﬁcity analysis. However, contrary to our expectation, we iden-
tiﬁed only a few new biomarker candidates from our analysis of
gene expression data across 23 tissues. We discussed several po-
tential problems in current omics approaches to cancer biomarker
discovery based on our analyses.
2. Materials and methods
2.1. Data collection, processing
Gene expression data sets were downloaded from Gene Expres-
sion Omnibus and ArrayExpress website. Human tissue gene
expression data sets generated using Affymetrix U133A and
U133Plus2 platform were collected. Detailed information on data
sets is given in Table S1. We preprocessed each data set from the
raw CEL ﬁles whenever available using MAS5 algorithm available
in affy package [13]. Data sets without raw CEL ﬁles were also in-
cluded in our study if they were processed using MAS5 algorithm.
Each sample was then normalized to a target mean density of 500
and then combined into two combined data sets (U133A and
U133Plus2, respectively) of approximately 10,000 human tissue
samples. The U133A chip contains 22,215 probe sets while
U133Plus2 contains 54,615 probe sets. The database is available
at http://medical-genome.kribb.re.kr/GENT/ with further informa-
tion [42].
2.2. Tissue speciﬁcity analysis
We used Shannon entropy (H) to measure the overall speciﬁcity
of a gene [40]. Given expression levels of a gene (g = 1,2, . . .,G) in N
tissues (t = 1,2, . . .,N), the relative expression of a gene g in a tissue
t was deﬁned as
ptjg ¼ wg;t=
X
16t6N
wg;t;
where wg,t is the expression level of the gene in the tissue. The en-
tropy of a gene’s expression distribution is calculated as
Hg ¼
X
16t6N
ptjglog2ðptjgÞ
A low entropy value represents a highly speciﬁc gene expression
pattern. However, while Shannon entropy provides a single metric
for assessing the complete gene expression proﬁle, it doesn’t pro-
vide any information on the tissues in which a gene may be specif-
ically expressed. A statistic, Qg|t, is introduced to measure the
degree of speciﬁcity of gene expression in each tissue type [40]:
Qgjt ¼ Hg  log2ðptjgÞ
A low Qg|t represents a highly speciﬁc expression pattern for
that tissue.We also used another method, ROKU, in a simulation study
[23,24]. Brieﬂy, a statistic U for identifying outliers was deﬁned as
U ¼ n logrþ
ﬃﬃﬃ
2
p
 s logn!
n
where n and s denote the numbers of non-outlier and outlier can-
didates and r denotes the standard deviation of the observations
of the n non-outlier calculation. Minimum U value and the number
of outliers (s) were detected for various combinations of outlier
candidates. Here, the number of outliers (s) was varied from 1 to
11. The best approximating combination is one that achieves the
lowest value for U and is termed the minimum AIC (Akaike Infor-
mation Criterion) estimate [23]. For details, please see Kadota
et al. [23]
2.3. Single tissue differential analysis (STDA) and multiple normal
tissues corrected differential analysis (MNTDA)
At ﬁrst, we tried to evaluate cancer biomarker candidates by
conventional single tissue differential analysis (STDA) which com-
pares gene expression values between each cancer patients and
controls [40]. Then, we designed a novel multiple normal tissues
corrected differential analysis (MNTDA) to identify potential serum
biomarkers for cancer patients. A ﬂowchart of our computational
approach is schematically shown in Fig. 1b.
For each tissue type, we categorized each sample into normal
or tumor tissues. To calculate expression level of each gene in
entire normal human tissues, we ﬁrst calculated a median value
of each gene for each tissue type. We used a median rather than
a mean value which is signiﬁcantly affected by a few outliers.
Then for each tissue, we computed multiple normal tissues
corrected gene expression value for cancer patients and normal
controls by adding the median values of all the other normal
tissues to the gene expression value of cancer patients and nor-
mal controls of a tissue of interest (Fig. 1b). Finally we applied t-
test to the multiple normal tissues corrected gene expression
values to identify potential serum biomarkers for each cancer
types [22]. Formal description of MNTDA is described as
followings.
We assume that there are t tissue types (t = 1,2, . . .,N), n normal
samples (j = 1,2,. . .,n) and m cancer samples (j = 1,2, . . .,m), and G
genes (i = 1,2, . . .,G). Of course, each tissue (t) has different number
of normal (n) and cancer (m) samples. Conventional differential
analysis (here, named as STDA) is performed by comparing two
group means
log2FCgit ¼
X
16j6m
log2ðgijtÞ=m
X
16j6n
log2ðgijtÞ=n
for each gene i and each tissue t.
In contrast, MNTDA is done as followings. First, for each tissue t
(t = 1,2,3, . . .,N), a median value of each gene i, medit =median(gijt)
is computed from gene expression values gijt of normal samples
j = 1,2, . . .,n.
Then, for each tissue t = 1,2, . . .,N, a corrected gene expression
value g’ijt is computed for each normal and tumor samples by add-
ing median gene expression values medit from other tissues except
the k tissue:
G0ijt ¼ gijt þ
X
16t<k
medit þ
X
kþ16t6N
medit
(j = 1,2, . . .,n (or m) , for normal (or cancer) samples.
Finally, MNTDA is performed by comparing two group means of
modiﬁed gene expression values
log2FCg
0
it ¼
X
16j6m
log2ðg0ijtÞ=m
X
16j6n
log2ðg0ijtÞ=n
Fig. 1. Two strategies for serum cancer biomarker discovery. (a) Tissue-speciﬁcity analysis. (b) Multiple normal tissues corrected differential analysis to identify potential
prostate cancer screening markers.
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on multiple hypothesis testing. FDR < 0.05 was considered as sig-
niﬁcant. All computations and statistical tests were performed
using R statistical language (http://cran.r-project.org/), Python pro-
gramming language (http://www.python.org/) and Microsoft Excel
software.
2.4. Simulation study
We performed a simulation study to compare MNTDAwith con-
ventional STDA combined with tissue-speciﬁcity analysis. First, we
generated a series of simulated data sets as illustrated in Fig. 2a.
We divided 23 tissues into x speciﬁc (or selective) tissues and
the remaining (23-x) non-speciﬁc tissues. Gene expression data
for non-speciﬁc tissues were generated by randomly sampling
100 samples from normal distribution with parameters
(mean = 100 and standard deviation = 30). Gene expression data
for speciﬁc (or selective) tissues were generated by randomly sam-
pling 100 samples from normal distribution with parameters
(mean = y and standard deviation = y  0.3; y = 100, 200, 500,
1000, 2000, 5000, 10,000). The number x of speciﬁc (or selective)
tissues was varied from 1 to 5, so up to ﬁve tissues are speciﬁcally
(or selectively) expressed in the simulation. Finally, we generated
gene expression data for a tumor tissue by randomly sampling
100 samples from normal distribution with parameters (mean = -
y  fc and standard deviation = y  fc  0.3; fc = 1, 2, 4, and 8). Thus,
a tissue-speciﬁc gene was allowed to be up-regulated up to eight-
fold compared to normal control.
With a simulated data set of 100 normal controls and 100 tumor
patients, we performed following analyses: MNTDA, conventional
single tissue differential analysis (STDA) combined with tissue
speciﬁcity analysis, and ROC analysis as a true answer. MNTDA
and STDA were performed as described above. We performed
two kinds of tissue speciﬁcity analysis, Shannon entropy and
ROKU. For ROC analysis, an expected serum level value for normalcontrols was calculated as the sum of 23 normal tissues while an
expected serum level value for cancer patients was calculated by
the sum of 22 normal tissues and one tumor tissue (Fig. 2b). The
AUC value was calculated for each simulated data set of 100 nor-
mal and 100 tumor samples by using ROCR package [43]. The
AUC was 1 for a simulated data set in which all of 100 tumor sam-
ples had higher expression value than all of 100 normal samples.
Different cut-offs for AUC were evaluated (Table C in Fig. 2). Then,
we evaluated if each method, that is MNTDA and STDA, could iden-
tify the marker in a simulated data set successfully, and summa-
rized the results as sensitivity and speciﬁcity. A python code for
the simulation study is given as a Supplementary ﬁle (Supplemen-
tary code 1).
2.5. Jackknife analysis
To demonstrate that our results are not affected by potentially
noisy data sets, we performed jackknife analysis. Brieﬂy, we re-
moved one data set from the combined data set, and repeated
the same analyses. We performed ten jackknife re-samplings and
calculated coefﬁcients of variations as the ratio of the standard
deviation (r) to the mean (l) of the ten re-sampled data sets.
Cv ¼ rl
We evaluated six parameters: Shannon entropy, sum of median
values across normal tissues, normal and tumor mean values in the
STDA, and normal and tumor mean values in the MNTDA in a
breast.
3. Results
3.1. Data sets
We collected 22,794 samples across 23 different tissues proﬁled
using Affymetrix U133A or U133Plus2 platforms (Table 1).
Fig. 2. A simulation study to compare performances of multiple normal tissues corrected differential analysis (MNTDA) with single tissue differential analysis (STDA)
combined with tissue speciﬁcity analysis. (a) A total of 14,000 simulated data sets representing 140 different conditions (100 data sets for each condition) were generated by
different combinations of x, y, and fc values (x: the number of speciﬁc tissues, y: the degree of speciﬁcity compared to non-speciﬁc tissues, and fc: fold increase relative to
normal counterpart). Each data set was generated by randomly sampling 2400 values (23 normal tissues + one tumor tissue; 100 values for each tissue) from normal
distribution with given parameters. (b) Evaluation of performances of multiple normal tissues corrected differential analysis with single tissue differential analysis combined
with tissue speciﬁcity analysis based on ROC analysis of each simulated data set. (C) Cut-offs for each analysis.
Table 1
Description of data sets used in study.
Tissue U133A U133Plus2 Total
Cancer Normal Cancer Normal Cancer Normal
Bladder 87 15 39 14 126 29
Blood 2907 1081 2079 283 4986 1364
Brain 592 1609 635 238 1227 1857
Breast 2589 103 1313 235 3902 338
Cervix 64 34 74 12 138 46
Colon 319 26 820 189 1139 215
Endometrium 0 9 72 61 72 70
Esophagus 24 28 13 9 37 37
Head_neck 21 2 202 14 223 16
Kidney 380 72 529 89 909 161
Liver 175 54 182 25 358 79
Lung 712 307 546 149 1258 456
Muscle 0 331 0 246 0 577
Ovary 341 9 613 8 954 17
Pancreas 13 7 132 54 145 61
Prostate 244 83 199 32 443 115
Skin 243 47 194 18 437 65
Small intestine 0 7 13 6 13 13
Spleen 0 16 4 5 4 21
Stomach 46 2 249 43 295 45
Testis 162 19 4 6 166 25
Thyroid 68 25 62 25 130 50
Uterus 0 22 152 12 152 34
Total 8987 3908 8126 1773 17,113 5681
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and 9899 samples were proﬁled using the U133Plus2 platform.
One concern on using global normalization for generating a
combined data set is that study-speciﬁc biases might affect results
of meta-analysis. We addressed this concern by performing jack-
knife re-sampling analysis on the original data sets. We randomly
deleted one data set at a time, and performed the same analyses
with the remaining data sets. We generated 10 jackknifed data sets
and calculated coefﬁcients of variations for each gene on two
parameters: Shannon entropy value and sum of median expression
across normal tissues. Also, in breast data sets, we performed the
same 10 jackknife re-samplings and calculated the following four
parameters: single tissue normal mean values in a breast, single
tissue cancer mean values in a breast, multiple normal tissues cor-
rected normal mean values in a breast, and multiple normal tissues
corrected cancer mean values in a breast. We found little variation
among jackknifed data sets as shown by small coefﬁcients of vari-
ation (Fig. S1). We presume that two factors, collecting many data
sets, and using a median instead of a mean during the MNTDA,
contribute to the robustness of the results.
Recently, we performed another analysis to assess the impact of
laboratory effects on publicly available data sets by following Lukk
et al’s method [33]. With a combined data set of 5089 samples of
92 biological groups produced in 93 laboratories, we found that
biological effects were stronger than the laboratory effects (data
available at http://medical-genome.kribb.re.kr/GENT/overview-
4.php). For details, please see Shin et al. [42].3.2. Expression pattern of good serum biomarkers across tissues
Several serum biomarkers are used in the clinic for screening,
prognosis, or monitoring of recurrence after surgical treatment[31,34]. To ﬁgure out important patterns of gene expression of
those clinical serum biomarkers, we ﬁrst examined their expres-
sion patterns across diverse normal and tumor tissues. Two of
them, PSA (prostate speciﬁc antigen) and AFP (alpha-feto protein),
are shown as representatives of serum biomarkers (Figs. S2 and
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ulated in prostate cancer patients compared to controls (Fig. S2).
AFP is not expressed in normal adults, but is abnormally over-ex-
pressed in a subset of liver and germ cell cancer patients
(Fig. S3). Thus, we ﬁgured out two important characteristics for a
successful serum biomarker. First, the gene should be expressed
in a tissue-speciﬁc manner or not expressed at all in normal tis-
sues. Second, the gene should be up-regulated in cancer patients
compared to normal controls.
3.3. Tissue speciﬁcity analysis
Our ﬁrst strategy to identify novel serum biomarkers for cancer
patients was to identify genes that are both expressed in a tissue-
speciﬁc manner and up-regulated in cancer patients compared to
controls (Fig. 1a). We performed tissue speciﬁcity analysis by using
Shannon entropy (H) and Q-statistics as explained in the Section 2.
Previous studies suggested that approximately two to ﬁve percent
of genes are expressed in a tissue speciﬁc manner [23,38]. For the
U133A and U133P2 data sets, we calculated H and Q values and
the percentage of tissue speciﬁc genes at each cut-off (Fig. S4). We
found that H < 3 was a reasonable choice as 3.6% (U133P2) and
3.9% of genes (U133A) were selected as tissue speciﬁc. For the Q va-
lue cut-off selection, we found that 0.156% (Q < 4), 0.289% (Q < 5),
0.557% (Q < 6), 1.34% (Q < 7) of genes were selected at each cutoff
in the U133P2 dataset, while 0.139% (Q < 4), 0.282% (Q < 5), 0.671%
(Q < 6), and 1.965% (Q < 7) of geneswere selected in theU133Adata-
sets. Q < 4 or Q < 5 would be a good choice for selecting tissue-spe-
ciﬁc genes strictly (please note that only 1 out 23 tissues will have
a low Q value while the others have high Q values). However, we
chose a rather loose cutoff of Q < 6 since we wished to select tissue
selective genes (that is expressed in a few tissues) as well.
For each tissue, we performed fold-change analysis and t-test to
identify differentially expressed genes between cancer patients
and normal controls [41]. Although several to tens of tissue-spe-
ciﬁc genes were identiﬁed for each tissue, few of them were up-
regulated in cancer patients compared to controls (Fig. 3). The only
tissue in which signiﬁcant proportions of tissue-speciﬁc genes
were up-regulated was a prostate (Fig. 3). KLK3 (PSA), KLK2
(PSA), and FOLH1 (PSMA) are examples of genes that are pros-
tate-speciﬁc and up-regulated in prostate cancer patients (Table 2)
[12,40,54]. KLK3 (PSA) is the most famous prostate-speciﬁc gene
used in the clinic. FOLH1 (folate hydrolase 1, formerly known as
prostate-speciﬁc membrane antigen) is a type II transmembrane
glycoprotein signiﬁcantly up-regulated in prostate tumors com-
pared to benign prostate hyperplasia tissues. CCL20 is a chemokine
suggested as a novel serum marker for nasopharyngeal carcinoma
detection and prediction of treatment outcomes, but its potential
as a serum marker for colon cancer is not yet tested [6]. Other
genes in Table 2 are located in the cytoplasm (KRT6A, KRT6B,
and PDZK1) or nucleus (WT1), so they are not suitable for serum
biomarkers.
In conclusion, few novel serum biomarker candidates were
identiﬁed by tissue-speciﬁcity analysis. To overcome this limita-
tion, we designed a novel approach, the multiple normal tissues
corrected differential analysis (MNTDA).
3.4. Multiple normal tissues corrected differential analysis (MNTDA)
Conventional single tissue DEG (differentially expressed gene)
analysis, which compares cancer and normal tissues, has produced
many gene lists as potential serum biomarkers for diagnosis and
screening of cancer patients. However, few of them were success-
fully validated in serum even though most of them are signiﬁcantly
up-regulated in tissues of cancer patients compared to normal con-
trols. We reasoned that secretion of the gene product from othernormal tissues into circulation would dilute the degree of up-reg-
ulation of the gene product in a tumor tissue [18]. We show this
point by an example (Fig. S5). REG1A (regenerating islet-derived
1A) is one of genes signiﬁcantly up-regulated in colon cancer pa-
tients compared to normal controls (log2-fc = 3.49; FDR < 9.4e-
35). Moreover, as it encodes a secreted protein, it seems to be a
good serum biomarker for colon cancer screening. However it is
highly expressed in normal pancreas as well as a few other tissues
such as small intestine and stomach (Fig. S5). The amount of
expression of REG1A in normal pancreas (60,000) is well above
the amount of expression in colon cancers (median 2000 with a
few samples over 10,000; Fig. S5). Thus, we can expect that the 8
to 10-fold increase of REG1A in colon cancer patients will not be
easily detected in the serum of the patients, as the increase is di-
luted by the overwhelming amounts of REG1A secreted by normal
pancreas, small intestine, and stomach tissues.
To simulate the environment in circulation, we designed a novel
method, the multiple normal tissues corrected differential analysis
(MNTDA), to identify genes that are expected to be signiﬁcantly
up-regulated even after their expressions in other normal tissues
are considered. The approach is shown in Fig. 2b and is explained
in the Section 2.
Typically, the expression of most up-regulated genes in STDA is
increased up to 30–50-fold in most tissues (Fig. 4). However, the
signiﬁcant up-regulation of most genes is almost abolished in
MNTDA (Fig. 4). For example, top 50 up-regulated genes in ovarian
cancer patients versus normal controls in STDA were increased be-
tween 30 and 500-fold, but the same 50 genes were increased only
1.1–2.3-fold in MNTDA (Fig. 4). This data again explains why few
markers were successfully validated in the clinic even if many po-
tential serum biomarkers have been identiﬁed through STDA.
3.5. Simulation study
One may argue that MNTDA is a simple integration of two
steps: STDA followed by tissue speciﬁcity analysis. To compare
MNTDA with STDA combined with tissue speciﬁcity analysis, we
generated a series of simulated data sets as described in Fig. 2,
and evaluated their performances in diverse simulated conditions.
For tissue speciﬁcity analysis, we evaluated two widely used meth-
ods: Shannon entropy and ROKU. By varying three parameters (x:
the number of speciﬁc tissues, y: the degree of speciﬁcity in com-
parison to non-speciﬁc tissues, and fc: fold increase relative to a
corresponding normal tissue), we generated a total of 14,000 data
sets representing 140 different conditions. Then, we set cut-offs for
each method as followings: log2(fc)P 1 for MNTDA, log2(fc)P 1
and E-value < 3.0 or log2(fc)P 1 and ROKU-value 6 100 for STDA
(Table C in Fig. 2).
In summary, MNTDA outperformed STDA with tissue speciﬁcity
analysis (either Entropy or ROKU) at all levels of AUC cut-offs (Ta-
ble 3). For example, when a true marker was deﬁned as a case with
AUC = 1, the sensitivity/speciﬁcity of MNTDA was 0.661/0.844
while those of STDA with Entropy or STDA with ROKU were
0.350/0.712 and 0.374/0.720, respectively (Table 3). In 32%
(1555/4934) cases, MNTDA could identify a true biomarker (that
is, AUC = 1) missed by STDA with ROKU method. Those conditions
included (y = 500 and fc = 8), (y = 1000 and fc = 8), (y = 2000 and
fc = 4), and (y = 2000 and fc = 8) (Fig. 5 and Table 4). In contrast,
MNTDA missed a true biomarker identiﬁed by STDA with ROKU
method in only 2.8% (137/1677) cases. Those conditions included
(y = 5000 and fc = 2 or 4) and (y = 10,000 and fc = 2 or 4)
(Table S2). Finally, 31% of true biomarkers were missed by both
MNTDA and STDA with tissue speciﬁcity analysis. True conditions
missed by both MNTDA and STDA with tissue speciﬁcity analysis
were (y = 100 and fc = 8), (y = 200 and fc = 4, or 8), and (y = 400
and fc = 4) (Table S2).
Fig. 3. Most tissue-speciﬁc genes are down-regulated in cancer patients. Tissue-speciﬁc genes were selected based on cut-offs (H < 3 and Q < 6) and their expression patterns
in each tissue were compared between tumors and normal controls. (a) U133A data set. (b) U133Plus2 data set.
Table 2
Up-regulated tissue-speciﬁc genes common to both U133Plus2 and U133A data sets.
id Symbol Tissue H (P2) Q (P2) log2fc (P2) FDR (P2)* H (A) Q (A) Log2fc (A) FDR (A)*
205476_at CCL20 Colon 2.96 5.2 1.45 0.0021 2.47 3.82 0.92 7.3E08
209125_at KRT6A Head_neck 2.27 4.91 0.68 0.723 2.42 5.03 0.01 0.983
213680_at KRT6B Head_neck 2.62 5.85 2.08 0.289 2.53 5.06 0.35 0.579
205380_at PDZK1 Liver 2.95 5.91 0.67 0.002 2.09 5.37 0.25 0.661
206067_s_at WT1 Ovary 2.88 5.77 0.69 0.570 2.75 5.69 0.48 0.733
204583_x_at KLK3 Prostate 2.16 2.72 1.74 7.6E-13 0.39 0.44 0.53 0.436
209854_s_at KLK2 Prostate 0.5 0.57 0.43 0.023 0.4 0.46 0.5 0.476
205860_x_at FOLH1 Prostate 1.64 4.61 0.71 0.003 2.9 4.13 1.34 0.002
* FDR: false discovery rate; in this table, FDR < 0.05 was not applied since too few genes are selected.
Fig. 4. Most highly up-regulated genes in tumors compared to normal controls are not good serum biomarkers. Each of top-50 genes identiﬁed in single tissue differential
analysis are minimally up-regulated in multiple normal tissues corrected differential analysis. (a) U133A data set. (b) U133Plus2 data set.
Table 3
Summary of simulation study.
AUC MNTDA STDA + entropy STDA + ROKU
1.00 *0.661/0.844 0.350/0.712 0.374/0.720
0.95 0.452/0.628 0.316/0.553 0.335/0.561
0.90 0.393/0.525 0.302/0.476 0.321/0.485
0.85 0.358/0.448 0.302/0.423 0.317/0.430
0.80 0.338/0.399 0.294/0.384 0.306/0.388
0.75 0.330/0.376 0.287/0.361 0.299/0.365
0.70 0.323/0.356 0.281/0.342 0.292/0.345
* Values represent sensitivity/speciﬁcity.
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Through the MNTDA, we have identiﬁed some tens of genes
that are signiﬁcantly up-regulated in cancer patients compared
to normal controls (see Tables 5 and 6). Among them are well-
known serum biomarkers such as KLK3 (=PSA) and MUC16
(=CA125) that are currently being used in the clinic [4,7,12]. MSLN
was shown to have adequate performance for ovarian cancer
screening to warrant further testing [9,37]. KLK2 and OR51E2 are
two promising biomarkers for prostate cancer diagnosis, prognosis,
and treatment [10,51]. Metastatic melanoma patients had higher
Fig. 5. Examples of simulated data sets in which a true biomarker was identiﬁed exclusively by multiple normal tissues corrected differential analysis (MNTDA).
Table 4
Conditions where true biomarkers were identiﬁed by MNTDA but missed by STDA combined with tissue speciﬁcity analysis in a simulation study.
y fc x (ts num) AUC Log2 (MNTFC) Log2 (STFC) E* Q* ROKU value ROKU ts num
500 8 1 1 1.23 3.08 4.32 6.76 65.91 1
500 8 2 1 1.23 3.09 4.20 6.85 66.17 2
500 8 3 1 1.12 3.08 4.13 6.95 63.79 3
500 8 4 1 1.02 3.08 4.09 7.07 59.15 4
1000 8 1 1 1.71 3.08 3.96 5.64 83.40 1
1000 8 2 1 1.71 3.07 3.74 5.77 83.12 2
1000 8 3 1 1.46 3.07 3.65 5.96 79.89 3
1000 8 4 1 1.28 3.08 3.63 6.20 75.21 4
1000 8 5 1 1.14 3.08 3.65 6.40 69.26 5
2000 4 1 1 1.32 2.08 3.33 4.41 99.57 1
2000 4 2 1 1.31 2.08 3.10 4.70 99.19 2
2000 4 3 1 1.01 2.08 3.08 5.08 95.24 3
2000 8 1 1 2.16 3.08 3.33 4.40 100.13 1
2000 8 2 1 2.16 3.09 3.10 4.71 99.04 2
2000 8 3 1 1.74 3.08 3.08 5.08 94.78 3
2000 8 4 1 1.47 3.08 3.14 5.45 89.43 4
2000 8 5 1 1.28 3.07 3.22 5.77 82.84 5
* E: Shannon entropy, Q: Q-value.
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regulation of MMPs and CXCL cytokines in diverse types of cancers
has been extensively investigated [5,8,51,53]. We listed relevant
references for other genes not discussed here (Tables 5 and 6).
However, we also found that many genes listed in Tables 5 and 6
are located in the nucleus or cytoplasm, so they are not good can-
didates for serum biomarkers [5].4. Discussion
The development of convenient serum bioassays for cancer
screening, diagnosis, prognosis, and monitoring of treatment is
one of top priorities among cancer research community [39].
The widespread use of various high-throughput technologies
has raised expectations that many useful serum bioassays will
soon be developed from voluminous data generated from omicstechnologies [25]. However, contrary to our expectation, the
number of approved serum biomarkers has not increased
[26,31]. Although thousands of potential cancer biomarkers have
been generated from gene expression proﬁling and proteomics
approaches, few of them have been successfully validated in the
clinical samples.
Using a data set of 22,794 tumor and normal samples across 23
tissues, we analyzed current problems and challenges of serum
biomarker discovery from gene expression data and found a few
important points. First, studying only a speciﬁc tissue of interest
is not enough for discovering serum biomarkers for the tissue.
For example, comparing only tumor and normal colon tissues is
not enough when one wants to discover novel serum biomarkers
for colon cancer. In Fig. S5, we showed that REG1A, signiﬁcantly
up-regulated in colon cancer patients compared to normal con-
trols, is unlikely to be a successful serum biomarker as it is highly
expressed in normal pancreas, small intestine, and stomach.
Table 5
Top 25 genes with high fold change values on MNTDA in U133Plus2 data set.
Affymetrix id Symbol Log2(fc) FDR E Q Tissue Cellular location Refs.
241550_at DPPA5 3.37 0.043 4.49 9.63 Testis Soluble, non-secreted –
204475_at MMP1 2.07 2.7e13 3 9.73 Head_neck Secreted [45]
220184_at NANOG 2.07 0.045 4.42 7.81 Testis Nucleus [19–21]
206427_s_at MLANA 1.86 2.5e05 3.34 5.43 Skin Nucleus [44]
1555505_a_at TYR 1.78 1.8e05 4.14 6.74 Skin Membrane [2,16,44]
231474_at C6orf221 1.61 0.046 4.49 7.74 Testis –
205959_at MMP13 1.58 0.0002 4.54 9.28 Head_neck Secreted [8]
206426_at MLANA 1.45 0.0001 3.83 6.05 Skin Nucleus [44]
205828_at MMP3 1.40 2.5e07 4.46 8.72 Head_neck Extracellular
236121_at OR51E2 1.39 4.8e08 4.06 6.31 Prostate Membrane [48,50]
209848_s_at SILV 1.32 0.0001 3.78 5.96 Skin Melanosome [29,46]
205680_at MMP10 1.31 5.14e05 4.54 8.9 Head_neck Secreted [53]
217428_s_at COL10A1 1.30 0 4.59 8.89 Breast Cytoplasm
204914_s_at SOX1 1.26 0 4.17 6.75 Brain Nucleus
37892_at COL11A1 1.26 0 3.83 8.54 Breast Cytoplasm
206224_at CST1 1.24 0.0416 4.28 9.65 Esophagus Secreted –
212909_at LYPD1 1.24 0.0086 3.78 7.49 Ovary –
214612_x_at MAGE6 1.22 7.37e05 2.67 8.84 Skin
210265_x_at POU5F1P3 1.20 0.0369 4.35 8.2 Testis –
206630_at TYR 1.17 3.1e06 4.27 6.96 Skin Membrane [2,16,44]
220196_at MUC16 1.15 0.0021 2.31 10.14 Ovary Soluble, non-secreted [7,35,37]
221266_s_at TM7SF4 1.14 0.0003 4.34 7.59 Thyroid Membrane [28]
1553830_s_at MAGEA2 1.13 0.0009 3.92 8.85 Skin Secreted
240366_at GPR143 1.09 0.00023 4.27 9.26 Skin Membrane
217428_s_at COL10A1 1.08 5.87e08 4.59 8.3 Pancreas Cytoplasm
Table 6
Top 25 genes with high fold change values on MNTDA in U133A data set.
Affymetrix id Symbol Log2(fc) FDR E Q Tissue Cellular location Refs.
206427_s_at MLANA 1.542 5.8e19 4.08 6.27 Skin Nucleus [44]
204885_s_at MSLN 1.36 1.74e5 2.54 8.91 Ovary Secreted [9,37]
204475_at MMP1 1.35 1.45e5 3.57 10.81 Esophagus Secreted [17]
209848_s_at SILV 1.25 2.63e18 4.2 7.41 Skin Melanosome [29,46]
204583_x_at KLK3 1.24 8.77e13 2.16 2.72 Prostate Secreted [12]
37892_at COL11A1 1.23 0.0028 4.14 10.25 Pancreas Cytoplasm –
220184_at NANOG 1.17 0.0005 4.04 8.62 Testis Nucleus [19–21]
37892_at COL11A1 1.13 1.8e40 4.14 8.69 Breast Cytoplasm [11]
204914_s_at SOX11 1.05 4.5e17 3.71 8.38 Kidney Nucleus –
206426_at MLANA 1.02 3.5e14 4.1 6.81 Skin Nucleus [44]
206696_at GPR143 1.01 3.8e14 3.84 8.67 Skin Membrane
206630_at TYR 0.97 4.1e17 4.17 7.74 Skin Membrane [2,16,44]
210339_s_at KLK2 0.97 1.3e15 3.77 5.3 Prostate Secreted protein [12]
206418_at NOX1 0.92 0.0001 2.51 3.21 Colon Multipass membrane [15,27]
217404_s_at COL2A1 0.89 1.5e14 3.69 7.33 Kidney Cytoplasm –
212236_x_at KRT17 0.87 0.0194 3.63 7.59 Head_neck Soluble, non-secreted [52]
209395_at CHI3L1 0.87 0 3.56 7.05 Brain
220196_at MUC16 0.86 0.0012 2.5 9.64 Ovary Soluble, non-secreted [4,37]
206286_s_at TDGF1 0.82 9.13e5 4.06 9.17 Testis Membrane [3]
206560_s_at MIA 0.82 1.28e10 3.84 7.68 Skin Extracellular [32]
204913_s_at SOX11 0.78 1.5e20 4.23 7.68 Kidney Nucleus –
214974_x_at CXCL5 0.78 0.0025 4.24 9.71 Pancreas Extracellular [14]
204915_s_at SOX11 0.80 9.2e18 4.33 9.48 Kidney Nucleus –
204475_at MMP1 0.76 9.1e5 3.57 9.31 Colon Secreted –
217428_s_at COL10A1 0.75 8.2e43 3.81 8.51 Breast Cytoplasm –
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tively expressed in pancreas (Shannon entropy 1.46 and Q-value
2.28), small intestine (Q-value 3.29), and stomach (Q-value 4.27),
but not in colon (Q-value 13.0). After tissue speciﬁcity analysis,
one would not select REG1A as a potential serum biomarker for co-
lon cancer. We suggest that for most biomarkers identiﬁed from
gene expression proﬁling, their pattern of expression in other nor-
mal tissues should be analyzed (i.e. by one of tissue speciﬁcity
analyses) before costly large-scale validation studies are initiated
on those markers. We provide a web database named GENT (Gene
Expression database of Normal and Tumor tissues; available at
http://medical-genome.kribb.re.kir/GENT/) to help users check
the pattern of expression of their interested genes across normal
and tumor tissues [42].To overcome the above-mentioned problem, we adopted two
strategies – tissue speciﬁcity analysis andMNTDA– in our computa-
tional approach to identify potential serum biomarkers from gene
expression data. The importance of tissue-speciﬁcity analysis in ser-
um biomarker discovery is well recognized among some research-
ers. Klee et al. rightly pointed out that tissue-speciﬁcity analysis
will help to prioritize serum biomarker candidates [26]. At ﬁrst,
weexpected thatmanynovel potential biomarkerswouldbediscov-
ered throughout tissues from our analysis. However, to our disap-
pointment, few novel biomarkers were identiﬁed (Table 2). While
some tens to hundreds of tissue-speciﬁc genes were identiﬁed from
each tissue, most of them were down-regulated in cancer patients
compared to controls (Fig. 3). This result is not surprising consider-
ing that carcinogenesis is a kind of de-differentiation process in
1084 H. Jin et al. / Journal of Biomedical Informatics 44 (2011) 1076–1085which tissue-speciﬁcity of a cell is gradually lost. Thus, our second
point is that novel serum biomarker is unlikely to be discovered
through tissue-speciﬁcity analysis.
Then to overcome the limit of tissue-speciﬁcity analysis, we de-
vised the MNTDA that might be useful for identifying potential ser-
um biomarkers. The basic rationale of the MNTDA is to artiﬁcially
simulate a circulation environment in which proteins are secreted
from all tissues in the body. Through a simulation study, we found
that, 32% of true biomarkers were identiﬁed by MNTDA but missed
by STDA with tissue speciﬁcity analysis (Fig. 5, Table 3, and
Table S2). Those cases are characterized by moderate tissue-spe-
ciﬁc expression where the gene expression in a speciﬁc tissue is
not overwhelmingly higher than gene expression in non-speciﬁc
tissues. Indeed, many potential serum biomarkers in Tables 5 and
6 are cases where genes are moderately tissue-speciﬁc but are
highly over-expressed in cancer patients compared to controls. In
contrast, only 2.8% of true biomarkers were identiﬁed by STDA
with tissue speciﬁcity analysis but not by MNTDA. Those cases
are characterized by highly tissue-speciﬁc expression with modest
over-expression in cancer patients compared to normal controls.
Finally, 31% of true biomarkers were missed by both MNTDA and
STDA with tissue speciﬁcity analysis. Those conditions are charac-
terized by low expression across all normal tissues followed by
high over-expression in cancer patients compared to normal con-
trols; Alpha-feto protein (AFP) can be a representative example.
Of course, our MNTDA is naïve in several points. First, differ-
ences in tissue sizes are ignored when we reproduce the circulation
environment from gene expression data of normal tissues. Obvi-
ously, tissues such as stomach, colon, and lung would secrete more
proteins in the circulation than smaller tissues such as pancreas
and bladder when a gene is expressed at the same level. Second,
only 23 out of more than 50 normal tissues were included in our
analysis. Third, the fact that tumors constitute only a minor portion
of a diseased tissue in most cancer patients is ignored in our anal-
ysis. Despite above-mentioned limits, our approach allows better
selection of likely serum biomarkers from gene expression data.
When we compared gene lists from STDA with those from MNTDA,
we found that many signiﬁcantly up-regulated genes (sometimes
up to 50-fold increase) in STDA were minimally up-regulated in
MNTDA since those genes were highly expressed in other normal
tissues, too (Fig. 4). We insist that many omics-derived candidates
that failed to pass clinical validation can be explained by the
above-mentioned rationale of MNTDA. Thus, our method has a po-
tential to improve the speciﬁcity of the process of identifying puta-
tive biomarkers by ﬁltering out many unpromising candidates.
Our MNTDA successfully identiﬁed two serum biomarkers in
the clinic (KLK3 and MUC16) and several potential biomarkers cur-
rently being evaluated (MSLN, KLK2, and OR51E2). Many other
genes in Tables 5 and 6 were identiﬁed as potentially useful bio-
markers in diverse cancer types, too. However, the number of
potentially useful serum biomarkers is disappointingly small. In
U133A data set, only 13 genes were over-expressed more than
twofold in MNTDA, while in U133Plus2 data set, only 62 genes
were over-expressed more than twofold. Because only about a half
of them encode secreted or membrane proteins, the number of
candidate serum biomarkers is again reduced. Our result can partly
explain why there have been so few new serum biomarkers in re-
cent years despite extensive omics studies [31]. Considering that
there are only a handful of potential serum biomarkers quantita-
tively different between cancer patients and normal controls, it
might be better to identify novel serum biomarkers with qualita-
tive differences such as post-translational modiﬁcations.
Although our study has focused only on gene expression data,
our conclusions are equally applicable to other types of molecular
markers. For example, because of the low abundance of potential
biomarker proteins in the serum, many researchers have appliedtwo-step approaches in their efforts to identify novel serum pro-
tein biomarkers [18]. They ﬁrst identiﬁed plausible candidate
markers by comparing tissues from cancer patients and normal
controls, and then tried to conﬁrm the candidate markers in the
serum with few successes [18]. We suggest that the pattern of
expression of those candidate markers in other tissues should be
examined before validating those markers in the serum. As tis-
sue-wide proteome expression databases are few, one may instead
refer to gene-expression database to examine if candidate markers
are abundantly expressed in other tissues.
Recently, DNA methylation markers have been extensively
examined as a new source of cancer screening serum biomarkers.
One of them, SEPT9, is being developed for blood-based colorectal
cancer screening [30]. Again, most researchers ﬁrst compare tumor
and normal tissues to identify candidate DNA biomarkers and then
try to validate their results in sera of patients. For the above-men-
tioned reason, we think that many potential DNA biomarkers iden-
tiﬁed from tissue analysis would not be useful when applied to
serum samples. As a DNA methylation map across different human
tissues is currently unavailable, examining the DNA methylation
pattern of candidate markers across other tissues would not be
easy. However, with next-generation sequencing machines such
as Illumina’s Genome Analyzer and Applied Biosystems’ SOLiD,
comparing DNA methylation patterns in sera of cancer patients
and normal controls has become a routine work. Therefore, com-
paring DNA methylation status in sera of cancer patients and con-
trols by next-generation sequencers would be a promising
approach to identify blood-based DNA methylation biomarkers
for cancer screening.
Our work has another implication. As most molecular biomark-
ers are diluted in the circulation, sampling molecular markers near
the diseased tissue is better strategy for molecular diagnosis. For
example, fecal DNA is better than serum DNA for colorectal cancer
screening [36], sputum DNA is better than serum DNA for lung
cancer screening [49], and urine specimen is normally used for
bladder cancer screening. For tumor types in which local sampling
of body ﬂuids is available, applying omics technologies such as
proteomics and next-generation sequencing to the body ﬂuids
would be better strategy to identify novel biomarkers.
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